PMID- 29951301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 10
IP  - Suppl 13
DP  - 2018 May
TI  - Immune checkpoint blockade for advanced non-small cell lung cancer: challenging 
      clinical scenarios.
PG  - S1494-S1502
LID - 10.21037/jtd.2018.01.80 [doi]
AB  - Immune checkpoint blockade has shown anti-tumour activity and improved survival 
      in advanced non-small cell lung cancer (NSCLC). A number of anti-PD-1/PD-L1 and 
      CTLA-4 monoclonal antibody agents have been evaluated in metastatic non-small 
      cell lung cancer. Nivolumab, pembrolizumab and atezolizumab are currently 
      approved for use in clinical practice due to demonstrated improvement in response 
      rate, overall survival (OS) and quality of life (QoL) over standard chemotherapy. 
      We present a series of cases that highlight the clinical challenges that these 
      novel agents present. A review of rare immune-related adverse events (AEs), 
      optimal treatment duration and patient selection will be presented. This series 
      will also address real-life clinical scenarios such as treatment re-challenge and 
      management of immune-related AEs.
FAU - Tay, Rebecca
AU  - Tay R
AD  - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, 
      UK.
FAU - Prelaj, Arsela
AU  - Prelaj A
AD  - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, 
      UK.
AD  - Department of Radiological, Pathological and Oncological Science, Sapienza 
      University of Rome, Roma, Italy.
FAU - Califano, Raffaele
AU  - Califano R
AD  - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, 
      UK.
AD  - Department of Medical Oncology, Manchester University NHS Foundation Trust, 
      Manchester, UK.
AD  - Division of Cancer Sciences, University of Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC5994491
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - adverse events (AEs)
OT  - atezolizumab
OT  - durvalumab
OT  - immune checkpoint blockade
OT  - nivolumab
OT  - pembrolizumab
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2018/06/29 06:00
MHDA- 2018/06/29 06:01
PMCR- 2018/05/01
CRDT- 2018/06/29 06:00
PHST- 2018/06/29 06:00 [entrez]
PHST- 2018/06/29 06:00 [pubmed]
PHST- 2018/06/29 06:01 [medline]
PHST- 2018/05/01 00:00 [pmc-release]
AID - jtd-10-S13-S1494 [pii]
AID - 10.21037/jtd.2018.01.80 [doi]
PST - ppublish
SO  - J Thorac Dis. 2018 May;10(Suppl 13):S1494-S1502. doi: 10.21037/jtd.2018.01.80.